Ectodomain-specific E-cadherin antibody suppresses skin SCC growth and reduces tumor grade: A multitargeted therapy modulating RTKs and the PTEN-p53-MDM2 axis

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1791-1802

  Brouxhon, Sabine M ^a   Kyrkanides, Stephanos ^a   Raja, Veena ^a   Silberfeld, Andrew ^a   Teng, Xiaofei ^a   Trochesset, Denise ^a,b   Cohen, Jason ^b   Ma, Li ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; INHIBITOR OF APOPTOSIS PROTEIN; LIVIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; SURVIVIN; UVOMORULIN; CADHERIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; IMMUNOHISTOCHEMISTRY; MOLECULAR THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOMA; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL GROWTH; DOWN REGULATION; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; RANDOMIZATION; SCID MOUSE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM GRADING; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904191340     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0971     Document Type: Article

References (50)

1. Cancer.org [Internet]. American Cancer Society Online Resources. Cancer Facts & Figures 2010. Available from: http://www.cancer.org/research/ cancerfactsstatistics/cancerfactsfigures2010/index. [Cited on November 1, 2013.]
2. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91. (Pubitemid 36459475)
3. Brouxhon S, Kyrkanides S, O'Banion MK, Johnson R, Pearce DA, Centola GM, et al. Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism. Cancer Res 2007;67:7654-64. (Pubitemid 47281358)
4. Brouxhon SM, Kyrkanides S, Teng X, Athar M, Ghazizadeh S, Simon M, et al. Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene 2014;33:225-35.
5. Chan AO, Chu KM, Lam SK, Wong BC, Kwok KF, Law S, et al. Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol 2003;21:2288-93. (Pubitemid 46621865)
6. Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 1994;69:580-5. (Pubitemid 24076484)
7. Brouxhon SM, Kyrkanides S, Teng X, O'Banion MK, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog 2013 Jun 18. [Epub ahead of print]
8. Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnajyan AM, et al. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 2003;9:6447-52. (Pubitemid 38031832)
9. Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Res 2011;71:629-33.
10. Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci 2012;125:4687-92.
11. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010;16:4325-30.
12. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001;98:11598-603. (Pubitemid 32928774)
13. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-82. (Pubitemid 34428742)
14. Yuspa SH, Hawley-Nelson P, Koehler B, Stanley JR. A survey of transformation markers in differentiating epidermal cell lines in culture. Cancer Res 1980;40:4694-703. (Pubitemid 11199740)
15. Brouxhon SM, Kyrkanides S, Teng X, Raja V, O'Banion MK, Clarke R, et al. Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways. Clin Cancer Res 2013;19:3234-46.
16. Ming M, He YY. PTEN: new insights into its regulation and function in skin cancer. J Invest Dermatol 2009;129:2109-12.
17. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-5. (Pubitemid 29190320)
18. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010;2:a001222.
19. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277:5484-9. (Pubitemid 34968598)
20. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002;27:462-7. (Pubitemid 35246255)
21. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/α, β-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 2001;61:5231-41. (Pubitemid 32681558)
22. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 2002;62:6891-900. (Pubitemid 35424078)
23. Galaz S, Espada J, Stockert JC, Pacheco M, Sanz-Rodríguez F, Arranz R, et al. Loss of E-cadherin mediated cell-cell adhesion as an early trigger of apoptosis induced by photodynamic treatment. J Cell Physiol 2005;205:86-96. (Pubitemid 41262854)
24. Kantak SS, Kramer RH. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 1998;273:16953-61. (Pubitemid 28311727)
25. Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer 2012;3:257-61.
26. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29:3419-26.
27. Madson JG, Lynch DT, Svoboda J, Ophardt R, Yanagida J, Putta SK, et al. Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis. Am J Pathol 2009;174:2357-66.
28. Kiguchi K, Bol D, Carbajal S, Beltrán L, Moats S, Chan K, et al. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 2000;19:4243-54.
29. Galer CE, Corey CL, Wang Z, Younes MN, Gomez-Rivera F, Jasser SA, et al. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011;33:189-98.
30. Mahajan K, Mahajan NP. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol 2012;227:3178-84.
31. Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997;14:1635-42. (Pubitemid 27198935)
32. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;9:355-8. (Pubitemid 39037083)
33. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012;122:464-72.
34. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
35. Bito T, Sumita N, Ashida M, Budiyanto A, Ueda M, Ichihashi M, et al. Inhibition of epidermal growth factor receptor and PI3K/Akt signaling suppresses cell proliferation and survival through regulation of Stat3 activation in human cutaneous squamous cell carcinoma. J Skin Cancer 2011;2011:874571.
36. Wilker E, Lu J, Rho O, Carbajal S, Beltrán L, DiGiovanni J. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. Mol Carcinog 2005;44:137-45. (Pubitemid 41397177)
37. Amornphimoltham P, Leelahavanichkul K, Molinolo A, Patel V, Gutkind JS. Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. Clin Cancer Res 2008;14:8094-101.
38. Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene 2007;26:3930-40. (Pubitemid 46884301)
39. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003;282:59-69. (Pubitemid 36259901)
40. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009;458:1127-30.
41. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, et al. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 2007;117:1893-901. (Pubitemid 47036323)
42. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303. (Pubitemid 27220767)
43. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403-14. (Pubitemid 351622014)
44. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7. (Pubitemid 28037193)
45. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation of PTEN transcription by p53. Mol Cell 2001;8:317-25. (Pubitemid 32831549)
46. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999;274:22932-40.
47. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, et al. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 2007;14:218-29. (Pubitemid 46092225)
48. Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, et al. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF-κB-dependent pathway. J Biol Chem 2007;282:3507-19. (Pubitemid 47084470)
49. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 2003;23:6139-49. (Pubitemid 37013092)
50. Gil A, Andrés-Pons A, Fernández E, Valiente M, Torres J, Cervera J, et al. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 2006;17:4002-13. (Pubitemid 44330883)